Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | EEF2K | O00418 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143965 | 0.84 | CYP2C9 (0.56) | PTGS1PTGS2ALOX5ERN1SRC | |
| SCHEMBL574999 | 0.84 | ALDH1A1 (0.52) | PTGS2ERN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL25142209 | 0.79 | PTGS1 (0.49) | PTGS1PTGS2ALOX5ALDH1A1SRC | |
| SCHEMBL29459647 | 0.78 | XDH (0.50) | PTGS2ERN1ALDH1A1CYP3A4TTR | |
| SCHEMBL29459683 | 0.78 | EGFR (0.53) | PTGS1PTGS2ALOX5ERN1ALDH1A1 | |
| SCHEMBL23464454 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SRCCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL565112 | 0.78 | XDH (0.50) | PTGS2ERN1ALDH1A1CYP3A4TTR | |
| SCHEMBL299751 | 0.78 | EGFR (0.53) | PTGS1PTGS2ALOX5ERN1ALDH1A1 | |
| SCHEMBL10330733 | 0.77 | ALDH1A1 (0.45) | ALDH1A1SRCCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL5646596 | 0.77 | ERN1 (0.56) | PTGS1PTGS2ALOX5ERN1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-20250136555-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4393909-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | Harbin Medisan Pharmaceutical Co., LTD. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4378931-A1 | TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF | Harbin Medisan Pharmaceutical Co., LTD. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023138302-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | 哈尔滨三联药业股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-114853686-B | Triazolone compound and medical application thereof | 中国药科大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-115894379-A | Hydantoin compound and medical application thereof | 中国药科大学 | 2023-04-04 | — | — | CN | disclosed |
| WO-2023024425-A1 | TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF | 中国药科大学 | 2023-03-02 | — | — | WO | disclosed |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| CN-1323291-A | Diaminopropionic acid derivatives | HOFFMANN LA ROCHE (CH) | 2001-11-21 | — | — | CN | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-1121342-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021920-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
| EP-0207454-B1 | ISOXAZOLE AND FURAN DERIVATIVES, THEIR PREPARATION AND USE AS ANTIVIRAL AGENTS | STERLING WINTHROP INC. (US) | 1992-09-09 | — | — | EP | disclosed |
| US-5002960-A | Viricides for combating picornaviruses | STERLING DRUG, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4939267-A | Viricides | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0207454-A2 | Isoxazole and furan derivatives, their preparation and use as antiviral agents | STERLING WINTHROP INC. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | PPARD, PPARA, PPARG | PTGS1 1762/4885PTGS2 2140/4885ALOX5 681/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | PTGS1 3620/4885PTGS2 3892/4885ALOX5 2751/4885 |
| US-20250136555-A1 | HYDANTOIN COMPOUND AND MEDICAL USE THEREOF | PPARD, PPARA, PPARG | PTGS1 553/4885PTGS2 855/4885ALOX5 1611/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | PTGS1 3824/4885PTGS2 4555/4885ALOX5 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.